1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
IRulya Therapeutics Inc.

IRulya Therapeutics Inc.

IRLA
IRulya Therapeutics Inc.US flagNASDAQ
33.23
USD
+3.23
- -
33.80MMarket Cap
IRulya Therapeutics Inc.
IRLA
(NASDAQ)

Recent

price

33.23

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-113.54
-115.78
-388
-526.79
-605.32
-308.45
-168.57
-262.71
-335.27
-40.43
Basic EPS, GAAP
-91.91
-110.5
-349.73
-348.71
-424.73
-263.74
-99.11
-148.68
-166.79
-20.55
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-155.92
-250.84
859.55
1,166.17
788.62
556.74
395.99
137.02
-128.18
-34.73
Book Value per Share
-155.92
-250.84
859.55
1,166.17
788.62
524.09
17.62
-135.9
-371.58
-34.73
Tangible Book Value per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
2
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
-12
-12
-37
-77
-90
-52
-31
-57
-84
-92
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
6
71
97
121
97
91
68
37
-20
115
Working Capital
7
- -
- -
- -
- -
- -
14
15
- -
- -
LT Debt
-20
-33
115
172
119
101
85
30
-36
-35
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
-53.42
-61.85
-47.14
-33.81
-98.63
- -
-440.68
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
18
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
1
1
Market Capitalization
187
14
19

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
23
26
123
Cash, Cash Equivalents & STI
18
18
116
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
43
9
8
Payables & Accruals
13
8
8
ST Debt
18
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-68.96%
-218.47%
Free Cash Flow
- -
8.01%
29.9%
Net Income, GAAP
- -
12.82%
47.78%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-51.84
-128.68
-25.45
- -
-262.71
2025
-68.41
-68.75
-49.83
- -
-335.27
2026
78.15
-12.31
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
NanoViricides, Inc. (NNVC)
RemeGen Co., Ltd. (9995.HK)
Halozyme Therapeutics, Inc. (0J2O.L)
Neith Corporation (6236.TWO)
Opiant Pharmaceuticals, Inc. (OPNT)
Caris Life Sciences, Inc. (CAI)
Business
IRulya Therapeutics is a clinical-stage biopharmaceutical company developing LAM-001, an inhaled formulation of rapamycin, for pulmonary diseases. Its clinical programs target pulmonary hypertension associated with interstitial lung disease, bronchiolitis obliterans syndrome after lung transplant, and sarcoidosis-associated pulmonary hypertension.

Company News

Company News APIChatGPT

  • globenewswire.com

    IRulya Therapeutics to Participate in the Craig-Hallum Biotech Catalyst Conference

  • defenseworld.net

    Quince Therapeutics (NASDAQ: QNCX) renames itself IRulya and sets IRLA ticker

  • globenewswire.com

    Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease

  • defenseworld.net

    Quince Therapeutics Stockholders Approve PIPE, Share Increase and Equity Plans

  • seekingalpha.com

    Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

  • seekingalpha.com

    Quince Therapeutics, Inc. (QNCX) Discusses LAM-001 Clinical Progress in Pulmonary Hypertension and Bronchiolitis Obliterans Syndrome Transcript

  • globenewswire.com

    Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026

  • globenewswire.com

    Quince Therapeutics to Participate in September 2026 Investor Conferences

  • globenewswire.com

    Quince Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Update

  • globenewswire.com

    Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

  • globenewswire.com

    Quince Therapeutics Appoints Recognized Leaders in Pulmonary Medicine to Scientific Advisory Board

  • seekingalpha.com

    Quince Therapeutics, Inc. (QNCX) Shareholder/Analyst Call Prepared Remarks Transcript

  • seekingalpha.com

    Quince Therapeutics, Inc. (QNCX) M&A Call Prepared Remarks Transcript

  • globenewswire.com

    UPDATE - Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

  • globenewswire.com

    Quince Therapeutics Announces Clinically Meaningful Improvements Across Functional, Hemodynamic and Biomarker Measures in Phase 2 Study in PAH and PH-ILD

  • globenewswire.com

    Quince Announces Acquisition of Orphai and up to $187 Million Private Placement to Advance Pulmonary Pipeline

  • businesswire.com

    Quince Therapeutics Settles Approximately $16.4 Million of Debt

  • defenseworld.net

    Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts

  • defenseworld.net

    Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Average Recommendation of “Reduce” by Analysts

  • feeds.benzinga.com

    What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours